Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Prepare for an IT career with this heavily discounted CompTIA bundle
The fight over a 'dangerous' ideology shaping AI debate
Hector Bellerin FC 24: How to Complete the Road to the Knockouts SBC
World to reckon with future of fossil fuels at COP28 climate summit
Get this plug-and-play 4K touchscreen monitor for under $300
Albania media guide
Take-Two's CEO: GTA 6 needs to be 'nothing short of perfection'
Union sues over changes in teacher evaluations prompted by Texas takeover of Houston school district